×

Dendreon Down

9:16 AM ET Wed, 9 May 2007

The FDA requested additional information from Dendreon on Provenge, the company's prostate cancer drug, and the stock collapsed as a result. Mike Huckman, CNBC pharmaceuticals reporter, has the details.